Ifm_05-may 2022 «COMPLETE × BUNDLE»

Patients are encouraged to discuss the balance between disease control and the toxic long-term effects of maintenance drugs with their oncology team.

If you are looking for guidance based on this study's results: IFM_05-May 2022

Lenalidomide was the primary drug used for maintenance in this study. Key Findings: Patients are encouraged to discuss the balance between

The (often referred to simply as the IFM-05 study) focused on using lenalidomide as a maintenance treatment. Due to the risk of secondary cancers identified

Due to the risk of secondary cancers identified in the IFM-05 trial, long-term monitoring for new symptoms or blood changes is standard practice for those on this regimen.

Research published around May 2022 explored the impact of "early" vs. "late" discontinuation (stopping before or after 3 years), noting that early stopping is often forced by toxicity rather than choice.

A significant number of patients (roughly 27%) had to stop the maintenance therapy early due to adverse side effects.